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Abstract
Purpose This study was designed to assess the clinical
outcomes of patients treated by vertebral augmentation
with nitinol endoprosthesis (VNE) to treat painful vertebral
compression fractures.
Methods Forty patients with one or more painful osteopo-
rotic VCF, confirmed by MRI and accompanied by back-pain
unresponsive to a minimum 2 months of conservative medical
treatment, underwent VNE at 42 levels. Preoperative and
postoperative pain measured with Visual Analog Scale (VAS),
disability measured by Oswestry Disability Index (ODI), and
vertebral height restoration (measured with 2-dimensional
reconstruction CT) were compared at last follow-up (average
follow-up 15 months). Cement extravasation, subsequent
fractures, and implant migration were recorded.
Results Long-term follow-up was obtained in 38 of 40
patients. Both VAS and ODI significantly improved from a
median of 8.0 (range 5–10) and 66 % (range 44–88 %) to 0.5
(range 0–8) and 6 % (range 6–66 %), respectively, at 1 year
(p \ 0.0001). Vertebral height measurements comparing time
points increased in a statistically significant manner (ANOVA,
p \ 0.001). Overall cement extravasation rate was 9.5 %.
Discal and venous leakage rates were 7.1 and 0 % respectively.
No symptomatic extravasations occurred. Five of 38 (13.1 %)
patients experienced new spontaneous, osteoporotic fractures.
No device change or migration was observed.
Conclusions VNE is a safe and effective procedure that is
able to provide long-lasting pain relief and durable verte-
bral height gain with a low rate of new fractures and
cement leakages.
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Introduction
Osteoporotic vertebral compression fractures (VCF) are
associated with postmenopausal bone loss. Sixteen percent
of women after menopause and 20 % of all adults older than
age 70 years suffer from vertebral compression fractures
[1].The main complication of VCF is acute pain, reported in
up to 84 % of patients with radiographic evidence of a
compression fracture [2]. Vertebroplasty and kyphoplasty
vertebral augmentation procedures have been shown to be
more effective than conservative treatment when treating
painful vertebral compression fractures [3, 4].
Vertebral body collapse associated with VCF can lead to
hyperkyphosis. The degree of hyperkyphosis depends upon
the number and severity of vertebral body fractures
(especially wedge-type VCF). Hyperkyphosis can produce
a reduction of pulmonary function and may lead to
increased risk for subsequent fracture(s) [5, 6]. In 1998,
the kyphoplasty procedure was developed to lift vertebral
endplates using inflatable, intervertebral balloon bone
tamps, with the goal of securing height restoration,
kyphosis reduction, and pain relief [7, 8]. Bone cement
polymethylmethacrylate (PMMA) injection follows
removal of the balloon for stabilization. Clinical experi-
ence has demonstrated a potential limitation of kyphoplasty
with loss of restored height after balloon deflation due to
vertebral elastic recoil. A nitinol vertebral endoprosthesis
has been designed to treat VCF, providing an intervertebral
scaffold that maintains height restored during the proce-
dure before cement injection. Less vertebral height loss
compared with kyphoplasty has been demonstrated [9, 10].
The VerteLiftTM System (SpineAlign Medical, Pleasan-
ton, CA) consists of nitinol implants designed to exert a force
from endplate to endplate, restoring lost height. This device
allows the preservation of cancellous bone and promotes
cement interdigitation and perfusion, which ultimately result
in height restoration and a potential for reduced fracture due
to a reduction in the stiffness of the treated vertebrae. For
these reasons and because of the possibility to reduce the
volume of the cement used, nitinol implants may offer sev-
eral advantages compared with kyphoplasty [9].
On these premises, we sought to assess the safety,
effectiveness, and vertebral height restoration of nitinol
endoprosthesis-assisted vertebroplasty and to analyze
maintenance of vertebral height, occurrence of new verte-
bral fractures, complications, and impact on perceived pain
and quality of life during long-term follow-up.
Materials and Methods
Population and Study Design
From December 2008 to September 2009, 40 patients (36
females; mean age 73.6 ± 8 years) were treated with
percutaneous vertebral augmentation performed by place-
ment of 84 nitinol endoprostheses (two devices in each
vertebra; two patients were treated for two vertebral frac-
tures) at a single institution. Patients were informed of
potential treatment-related complications and each pro-
vided signed, informed consent in accordance with the
Declaration of Helsinki. Outcome assessments were pre-
planned as part of the routine care of patients at our
institution. The internal review board approved this retro-
spective analysis.
Inclusion Criteria
• Age C55 years
• Osteoporotic vertebral fracture A1.1, A1.2 or A1.3
(Magerl’s classification)
• Bone marrow edema within the fracture assessed with
MRI
• Significant back pain (Visual Analogue Scale score C5)
• Tenderness to palpation over the spinous process of the
fractured vertebra
• Persistence of back pain after a minimum of 8 weeks
and no more than 12 weeks of conservative medical
treatment consisting of bisphosphonates or other bone
antiresorption agents and pain medications (nonsteroi-
dal anti-inflammatory drugs and/or oral or parenteral
opiates)
Exclusion Criteria
• Fracture A2, A3, B, and C (Magerl’s classification)
• Tumoral vertebral collapse
• Systemic infection or any suspicious infective
spondylodiskitis
• Uncorrectable coagulation disorders
• Nerve root pain or neurological deficit due to the
fracture
Technique
Procedures were performed in an angiography room
equipped with flat-panel digital fluoroscopy with rotational
acquisition and computed tomography (CT)-like multipla-
nar reconstructions (MPR) (Allura Xper CT; Philips, the
Netherlands). Patient’s heart rate, pulse oximetry, and
blood pressure were monitored continuously throughout
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the procedure. All procedures were performed with local
anesthesia by injection of 2 mL or less of 2 % lidocaine
hydrochloride using a 22-gauge Quincke needle, adminis-
tered percutaneously over the pedicle periosteum. Access
cannulae were inserted using the oblique projection and
then advanced in the anteroposterior (AP) projection to the
medial aspect of the pedicle. CT scan was performed to
assess the correct cannula positioning and to measure pre-
procedural vertebral height. The delivery pathway for the
implant was created using trocars and a coaxial manual
drill through transpedicular cannulae (Fig. 1). Bone tissue
removed during drilling was gathered for histological
examination.
The implants were delivered through the access cannu-
lae (diameter 8 gauges), and the implants were positioned
and deployed using a multifunctional handle (actuates the
collapse and opening of the implant) attached to the
delivery system. The nitinol implants were positioned and
adjusted under fluoroscopy approximating an ‘‘XX’’ image
in the AP projection (Fig. 2). This ‘‘XX’’ intervertebral
orientation allows the device struts to deliver height res-
toration force to the endplates. When the implants were
properly positioned and expanded, the delivery system was
detached.
Injection cannulae were prefilled with polymethyl-
methacrylate (KyphX HV-R; Elmdown LTD. London,
England). When the cement reached a viscosity similar to
‘‘toothpaste consistency,’’ the prefilled cannulae were
coaxially advanced through the working cannulae to the
distal end of the implant. Cement injection was performed
manually under continuous fluoroscopic monitoring
(Fig. 3). An average of 5 mL of PMMA was injected per
level. Cement injection was stopped when satisfactory
intervertebral interdigitation and cement distribution was
observed. When cement injection was complete, the can-
nulae were withdrawn. CT scan was performed to record
postprocedural vertebral height measurements, to assess
complications, and to record any extravasation (Fig. 3).
Device
The VerteLift endovertebral prosthesis used in this study is
a nitinol (nickel/titanium alloy) cage CE Marked for
treatment of vertebral body fractures resulting from
Fig. 1 Fluoroscopic lateral
view during manual drilling to
create the channels for the
implant; CT-like axial
multiplanar reconstruction to
assess needle correct pathway
and to measure vertebral height
before implant expansion
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osteoporosis, tumor, or trauma. The implants are available
in four heights (14, 16, 18, and 20 mm), and each height is
available in symmetric and asymmetric configurations
suitable for concave/biconcave and wedge-type vertebral
compression fractures, respectively. The nitinol implant is
designed to be collapsed and expanded multiple times
allowing proper positioning of each implant and can be
withdrawn through the cannula when completely expanded
(if necessary), before PMMA injection; this characteristic
is unique compared to other endovertebral stents, allowing
Fig. 2 Nitinol implants in the open fashion in lateral view and in the
anteroposterior view (XX fashion) before and after detachment from
delivery system using handles (‘‘amber’’ prototype) under
fluoroscopic guidance. On the right, the implant in the closed and
in the open fashion (asymmetric)
Fig. 3 PMMA injection. Prefilled cannulae with blunt-tip pusher and the nitinol implants encased in bone cement. CT multiplanar reconstruction
was performed for height measurements after implant expansion and PMMA injection
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a more precise and safer positioning. The transpedicular
channel is created with a manual drill. The nitinol implant
and delivery device is inserted into a handle, which allows
expansion, positioning, and collapsing of the implant with
manual rotation and actuation of directional switches. The
implant is collapsed for insertion through transpedicular
working cannulae. A transpedicular access kit is available
comprised of two 8 gauges (4.8 mm) diameter working
cannulae, two pedicle trocars (11 gauges), a manual drill
(11 gauges), and six cement injection cannulae.
Radiological Assessment and Vertebral Height
Measurements
Vertebral height was measured immediately before and
after vertebral augmentation with CT-like multi-planar
reconstruction (MPR) obtained by angiographic imaging
equipment. Six measurements were taken for each treated
level: left, central, and right in the midcoronal recon-
struction and anterior, central, and posterior in the mid-
sagittal reconstruction. A CT scan (LightSpeed16; General
Electric, Milwaukee, WI) was performed on each patient
1 year postprocedure to check implant position and to
repeat measurements. On the same day, a standing plain
radiograph of the spine was taken to assess spine align-
ment, fracture stability, and occurrence of new fractures.
Two independent radiologists, blinded to clinical out-
comes, performed CT measurements and plain film
evaluations.
Pain and Quality of Life Assessment
Patients were asked to rate their perceived pain using a
visual analog scale (VAS) of 0–10 where 0 is no pain and
10 is the worst pain imaginable. VAS scores were collected
preprocedure (baseline), 24 h postprocedure, and 1 year
postprocedure. A reduction of C2 points on the VAS scale
was considered clinically significant [11].
Quality of life (QoL) was assessed using the Oswestry
Disability Index (ODI) by administering a questionnaire at
the time of clinical interview (baseline), 2 weeks (postpro-
cedure), and 1 year after the procedure. A postprocedural
reduction of C15 points was considered clinically significant
[12]. In addition to the evaluations at the planned time points,
all patients received standard clinical follow-up.
Statistical Methods
CT measurements of vertebral height followed a normal
distribution and therefore means and standard deviations
were used as summary statistics for this variable. Baseline,
postprocedural and 1-year vertebral height measurements
were compared by analysis of variance (ANOVA) with
repeated measures. Pairwise comparisons of vertebral
height at different time points were performed by the
paired Student’s t test.
Because VAS and ODI scores did not follow a normal
distribution, medians and their ranges were used as sum-
mary statistics and comparisons were performed by non-
parametric tests. Baseline, postprocedural and 1-year VAS
and ODI scores were compared by the Friedman test.
Pairwise comparisons of VAS and ODI scores at different
time points were performed by the Wilcoxon test. Statis-
tical analyses were performed by the SPSS version 17
statistical package (IBM; Chicago, IL), and significance
was set at p \ 0.05. For multiple comparisons, the Bon-
ferroni correction was applied, so that statistical signifi-
cance was set at p \ 0.017 (0.05/3).
Study Limitations
Our Study has Some Limitations:
• Retrospective cohort study, although eligibility and
assessments were preplanned.
• Nonrandomized design
• Small number of patients
• No measurements of the Kyphosis angle
• The procedure may be technically complex and time-
consuming.
Results
All implants were successfully delivered, positioned, and
secured in all study patients. No major complications or
perioperative deaths occurred. No venous PMMA leakages
were detected during the procedure or with postprocedural
CT. Mild asymptomatic cement leakages were detected in
4 of 42 treated levels: one para-pedicular and three inside
the vertebral disc. The overall leakage rate was 9.5 % and
discal rate was 7.1 %. During follow-up, no device change
or migration was observed by blinded radiologists.
Vertebral height measurement, VAS, and ODI scores
were available at the baseline and after the procedure
(within 24 h and at 2 weeks for VAS and ODI, respectively)
for all 40 patients and at 1-year follow-up for 38 patients
(median follow-up 15 months; range 11–21 months). Two
patients did not complete the 1-year follow-up: patient #30
experienced incomplete pain relief requiring surgical fixa-
tion for an underlying mild listhesis, and patient #22 died
6 months postprocedure due to a coronary event unrelated
to the procedure.
Table 1 changes in vertebral height are summarized in
Table 2. Vertebral height measurements were statistically
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significant (ANOVA with repeated measures, p \ 0.001).
Compared with baseline values, vertebral height was sig-
nificantly increased immediately after the procedure and at
the 1-year time point. Conversely, no statistically signifi-
cant difference between postprocedural and 1-year height
measurements were observed, indicating that increases in
height obtained with the procedure were stable and long-
lasting (Fig. 4).
Median VAS scores at baseline (preprocedure), within
24 h, and at 1 year postprocedure were: 8.0 (range 5–10), 0
(range 0–8), and 0.5 (range 0–8), respectively
(p \ 0.0001). Although all patients achieved a VAS
improvement of at least two points, patient #30 with
baseline VAS score of ten still had significant pain after the
procedure due to underlying listhesis. At 1 year postpro-
cedure, 5 of 38 patients (13 %) had experienced pain
increase (C2 points VAS score increase) compared with
initial postprocedural values (Fig. 5). Multiple compari-
sons showed that both postprocedural and 1-year VAS
scores were significantly reduced compared with the
baseline (p \ 0.001 for both comparisons). Conversely, the
difference between postprocedural and 1-year scores was
not considered statistically significant (p = 0.06).
Median ODI scores at baseline (preprocedure), 14 days,
and at 1 year postprocedure were: 66 % (range 44–88 %),
4 % (0–82 %), and 6 % (range 6–66 %), respectively
(p \ 0.001). At 1 year, the majority of patients maintained
the ODI score achieved at the initial postprocedural time
point (Fig. 6). Multiple comparisons showed initial post-
procedural and 1-year scores were significantly reduced
compared with the baseline (p \ 0.001 for both compari-
sons). Conversely, the difference between day 14 and
1-year scores was not statistically significant (p = 0.176).
Seven patients experienced new vertebral fractures
during follow-up, for an overall subsequent fracture rate of
18.4 %. Patient #2 experienced a high-energy trauma (fell
down stairs) 2 weeks after vertebral augmentation. Patient
#19 was diagnosed with multiple myeloma at biopsy. Five
additional patients experienced new spontaneous, osteo-
porotic fractures, which equates to a new fracture rate of
13.1 %; all fractures were at adjacent levels. Three frac-
tures were detected on the levels above the treated vertebra
(all spontaneous) and four on the level below (including
two spontaneous, one traumatic, and one in the patient with
myeloma).
Discussion
Vertebral augmentation performed with the nitinol implant
system was demonstrated to be safe in this series of
patients. No major complications or unanticipated adverse
events occurred during the intervention or at 1-year follow-T
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up. No venous cement leakages were observed, and the 84
implanted devices exhibited no positional change or
observable migration through 1-year follow-up.
There is minimal data published on intervertebral
implants for the treatment of vertebral compression frac-
tures, but occurrence of implant migration is not likely to
happen as the devices utilize PMMA to provide long-term
stabilization and anchoring by surrounding the implant
itself. One adverse event was reported in FDA MAUDE
database for delayed migration of an implant approved for
vertebral body replacement (StaXx XD Expandable
Device; Spine Wave, Shelton, CT) 3 months after
intervention, requiring surgical removal [13]. Because
vertebral augmentation is routinely performed percutane-
ously, an important goal is to minimize complications
requiring surgical revision as a result of malpositioning or
migration of the implant.
The method of vertebral augmentation in this study was
effective in terms of immediate pain relief and quality of
life improvement. The improvements in VAS and ODI
were durable, lasting through 1-year follow-up, which
constituted the main endpoints of this study. The nitinol
implant has the theoretical advantage to prevent loss of
vertebral height intraoperatively and postoperatively by
Table 2 Summary of vertebral height measurements at each time point
Measure Baseline Postprocedural 1-year Diff. post-procedural
versus baseline
p Diff. 1 year
versus baseline
p Diff. 1 year versus
postprocdural
p
Mid coronal
Left 19.6 (4.7) 22.0 (4.4) 21.2 (4.6) 2.5 (2.4) \0.001 1.7 (2.4) \0.001 -0.7 (2.4) 0.07
Center 13.2 (4.4) 17.2 (3.5) 17.0 (3.4) 3.9 (2.9) \0.001 3.8 (2.7) \0.001 -0.14 (2.1) 0.684
Right 19.0 (4.5) 20.6 (4.5) 21.0 (4.0) 1.6 (1.9) \0.001 2.0 (2.1) \0.001 0.39 (1.7) 0.156
Mid sagittal
Anterior 17.2 (5.6) 19.4 (5.0) 19.2 (5.3) 2.3 (2.3) \0.001 2.1 (2.8) \0.001 -0.20 (2.5) 0.611
Center 12.2 (4.5) 16.9 (2.9) 16.4 (2.9) 4.7 (3.6) \0.001 4.2 (3.2) \0.001 -0.5 (1.9) 0.096
Posterior 21.7 (3.9) 23.7 (2.9) 23.6 (3.6) 2.0 (2.2) \0.001 1.5 (2.7) 0.001 -0.44 (2.2) 0.215
Cells report mean values in millimeters with standard deviations in parentheses
Fig. 4 Changes in vertebral height at different time points in
midcoronal (A left; B center; C right) and in midsagittal (D, anterior;
E, center; F, posterior) reconstructions. Circles represent mean values
and bar represent standard deviations. The dashed line is drawn at the
baseline value on the y axis
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exerting an endplate to endplate lifting that is sustained
until bone cement injection and is permanently maintained
after polymerization of the PMMA. It has been observed
during balloon kyphoplasty procedures that vertebral
height restored during inflation of the bone tamp can be lost
after balloon deflation due to elastic recoil of the vertebral
body. This has been demonstrated in an in vitro study
where anterior height loss was significantly higher in bal-
loon kyphoplasty compared with vertebral body stenting
(VBS): 12 versus 4 %, respectively (p = 0.003) [9]. Both
kyphoplasty and VBS rely on balloon-assisted vertebral
fracture reduction methods. The presence of an internal,
permanent scaffold in the VBS prevents elastic recoil and
loss of restored vertebral height. Current VBS technology
compared with the nitinol implant used in this study is not
easily retrievable or repositionable after expansion,
because it is designed for single-stage, permanent deploy-
ment. VBS also creates greater bone compaction upon
inflation of the expansion balloon. The VBS cavity creating
procedure may create less chance for cement interdigita-
tion. Furthermore, VBS cannot reach endplate to endplate,
because the stents are smaller in diameter than vertebral
body height.
VerteLift access cannulae diameter of 8 gauge is the same as
balloon kyphoplasty and other endovertebral stent instrumen-
tation but larger than percutaneous vertebroplasty needle
(usually 13 gauges); this should be considered in terms of
minimally invasive procedure. Moreover, this procedure
requires bipedicular cannulation and is therefore more time
consuming (average procedural time of 45 min) than a unipe-
dicular approach, which is usually adequate for vertebroplasty.
In this series of 40 patients, vertebral height was mea-
sured in the central point of the endplates. Highest gains
were found in the central measurement taken in midcoronal
(3.9 mm ± 2.9) and in midsagittal reconstruction
(4.7 mm ± 3.6). It is possible that height restoration at the
point of maximum loss in some patients was greater than
the mean values reported because the greatest height loss
may have occurred outside the midcoronal or midsagittal
plane. Vertebral height restoration was stabilized by the
cemented nitinol implant. No statistically significant height
loss was detected at 1-year follow-up, whereas height loss
at 1-year follow-up for kyphoplasty [14] and vertebroplasty
[15] has been reported in the literature.
A comparative trial involving balloon kyphoplasty and a
titanium implant was performed in a biomechanical in vitro
study [9]. Significantly greater vertebral height loss
(p \ 0.025) was detected after reconstruction with kyp-
hoplasty repair compared with the titanium mesh implant.
The biomechanical properties of the two repair techniques
were not found to be statistically different, whereas the
amount of bone cement required for the titanium implant was
less than for kyphoplasty. Cancellous bone was more likely to
be preserved with the mesh device, creating a smaller void.
The nitinol implant has been shown to provide endplate-
to-endplate partial lifting capabilities in this series, with the
additional value of nearly unlimited positioning, reposi-
tioning, and retrieval before PMMA injection to achieve
optimal vertebral reconstruction. The placement and
deployment of the nitinol implant provided predictable,
intraoperative vertebral height restoration while preserving
cancellous bone. It is likely that preserved cancellous bone
provides for effective cement interdigitation and lower
volumes of PMMA injection (average 5 mL) necessary for
stabilization compared to kyphoplasty procedures. This
may be an important observation as the amount and the
distribution of bone cement has been associated with the
incidence of a subsequent adjacent vertebral fracture [16].
In our experience, all new fractures were located at the
adjacent levels, which usually occurs with osteoporotic
patients, even if all of them were under medical therapy for
osteoporosis before and after the procedure. However, the
incidence of new spontaneous vertebral fractures was
13.1 %, which compares favorably with the lower value
Fig. 5 Changes in VAS scores at different time points. Each line
represents a patient
Fig. 6 Changes in ODI scores at different time points. Each line
represents a patient
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ranges reported in other vertebral augmentation
procedures.
Conclusions
Vertebral augmentation performed with the nitinol implant
is an effective procedure, producing immediate and long-
term pain relief, significant improvement in QoL, and
durable height restoration with a good safety profile.
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